Showing 1261-1270 of 3103 results for "".
- FDA Approves Ocrevus for Pediatric Relapsing-Remitting MShttps://practicalneurology.com/news/fda-approves-ocrevus-for-pediatric-relapsing-remitting-ms/2487037/
- BTK Inhibitor Compared With Ocrelizumab for Primary Progressive MShttps://practicalneurology.com/news/btk-inhibitor-compared-with-ocrelizumab-for-primary-progressive-ms/2485636/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026 demonstrated that fenebrutinib (Roche, Basel, Switzerland), an investigational oral Bruton tyrosine kinase (BTK) inhibitor, achieved noninferior efficacy compared with Ocrevus (
- Tolebrutinib vs Teriflunomide Treatment for Individuals with Relapsing MShttps://practicalneurology.com/news/study-compares-tolebrutinib-vs-teriflunomide-as-treatment-for-individuals-with-relapsing-ms/2473966/Analysis of results from two clinical trials presented at the American Academy of Neurology (AAN) 2025 Annual Meeting revealed no significant difference in the adjusted annualized relapse rate (ARR) in individuals with relapsing multiple sclerosis (RMS) treated with either tolebrutinib (Sanofi; B
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Standard Health Outcomes Recommended for Relapsing-Remitting MShttps://practicalneurology.com/news/standard-health-outcomes-recommended-for-relapsing-remitting-ms/2470122/A multidisciplinary scientific committee reported on their initiative to define a set of standard health outcomes for relapsing-remitting multiple sclerosis (R
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Biosimilar Found Equivalent to Natalizumab for Relapsing-Remitting MShttps://practicalneurology.com/news/biosimilar-found-equivalent-to-natalizumab-for-relapsing-remitting-ms/2470108/
- Masitinib Reduced Disability Progression in People With Progressive MShttps://practicalneurology.com/news/masitinib-reduced-disability-progression-in-people-with-progressive-ms/2469840/As published in Neurology Neuroimmunology & Neuroinflammation, results from a phase 3 trial (NCT01433497) of masitinib (AB Science; Paris, Franc
- Ludwig Kappos, MD, Awarded 2026 John Dystel Prize for MS Research, to Present at AAN 2026https://practicalneurology.com/news/ludwig-kappos-md-awarded-2026-john-dystel-prize-for-ms-research-to-present-at-aan-2026/2486639/
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of